<DOC>
	<DOCNO>NCT00876486</DOCNO>
	<brief_summary>Phase III trial evaluate efficacy safety Genexol速-PM compare Genexol速 subject recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Evaluate Efficacy Safety Genexol速-PM Compared Genexol速 Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Subjects meet follow criterion participate trial . 1 . Subjects age 18 year old . 2 . Subjects whose write informed consent obtain comply local regulatory requirement prior participation trial . 3 . Subjects histologically cytologically confirm breast cancer evidence recurrence metastasis . 4 . If subject receive Taxanes neoadjuvant adjuvant therapy , subject relapse breast cancer 12 month complete neoadjuvant adjuvant therapy Taxanes . 5 . Subjects measurable disease accordance RECIST criterion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>